A Comparison of Protein Stability in Prefillable Syringes Made of Glass and Plastic

References

1. 1.↵
   1. Carpenter J. F.,
   2. Randolph T. W.,
   3. Jiskoot W.,
   4. Crommelin D. J.,
   5. Middaugh C. R.,
   6. Winter G.,
   7. Fan Y. X.,
   8. Kirshner S.,
   9. Verthelyi D.,
   10. Kozlowski S.,
   11. Clouse K. A.,
   12. Swann P. G.,
   13. Rosenberg A.,
   14. Cherney B.

   Overlooking Subvisible Particles in Therapeutic Protein Products: Gaps That May Compromise Product Quality. J. Pharm. Sci. 2009, 98 (4), 1201–1205.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Rosenberg A. S.

   Effects of Protein Aggregates: An Immunologic Perspective. AAPS J. 2006, 8 (3), E501–E507.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Purcell R. T.,
   2. Lockey R. F.

   Immunologic Responses to Therapeutic Biologic Agents. J. Investig. Allergol. Clin. Immunol. 2008, 18 (5), 335–342.

   OpenUrlPubMed
4. 4.↵
   1. Singh S. K.,
   2. Afonina N.,
   3. Awwad M.,
   4. Bechtold-Peters K.,
   5. Blue J. T.,
   6. Chou D.,
   7. Cromwell M.,
   8. Krause H. J.,
   9. Mahler H. C.,
   10. Meyer B. K.,
   11. Narhi L.,
   12. Nesta D. P.,
   13. Spitznagel T.

   An Industry Perspective on the Monitoring of Subvisible Particles as a Quality Attribute for Protein Therapeutics. J. Pharm. Sci. 2010, 99 (8), 3302–3321.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Jones L. S.,
   2. Kaufmann A.,
   3. Middaugh C. R.

   Silicone Oil Induced Aggregation of Proteins. J. Pharm. Sci. 2005, 94 (4), 918–927.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Thirumangalathu R.,
   2. Krishnan S.,
   3. Ricci M. S.,
   4. Brems D. N.,
   5. Randolph T. W.,
   6. Carpenter J. F.

   Silicone Oil- and Agitation-Induced Aggregation of a Monoclonal Antibody in Aqueous Solution. J. Pharm. Sci. 2009, 98 (9), 3167–3181.

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   1. Felsovalyi F.,
   2. Janvier S.,
   3. Jouffray S.,
   4. Soukiassian H.,
   5. Mangiagalli P.

   Silicone-Oil-Based Subvisible Particles: Their Detection, Interactions, and Regulation in Prefilled Container Closure Systems for Biopharmaceuticals. J. Pharm. Sci. 2012, 101 (12), 4569–4583.

   OpenUrlPubMed
8. 8.↵
   1. Gerhardt A.,
   2. McGraw N. R.,
   3. Schwartz D. K.,
   4. Bee J. S.,
   5. Carpenter J. F.,
   6. Randolph T. W.

   Protein Aggregation and Particle Formation in Prefilled Glass Syringes. J. Pharm. Sci. 2014, 103 (6), 1601–1612.

   OpenUrl
9. 9.↵
   1. Liu W.,
   2. Swift R.,
   3. Torraca G.,
   4. Nashed-Samuel Y.,
   5. Wen Z.-Q.,
   6. Jiang Y.,
   7. Vance A.,
   8. Mire-Sluis A.,
   9. Freund E.,
   10. Davis J.,
   11. Narhi L.

   Root Cause Analysis of Tungsten-Induced Protein Aggregation in Pre-filled Syringes. PDA J. Pharm. Sci. Technol. 2010, 64 (1), 11–19.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Bee J. S.,
    2. Nelson. S. A.,
    3. Freund E.,
    4. Carpenter J. F.,
    5. Randolph T. W.

    Precipitation of a Monoclonal Antibody by Soluble Tungsten. J. Pharm. Sci. 2009, 98 (9), 3290–3301.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Jiang Y.,
    2. Nashed-Samuel Y.,
    3. Li C.,
    4. Liu W.,
    5. Pollastrini J.,
    6. Mallard D.,
    7. Wen Z.-Q.,
    8. Fujimori K.,
    9. Pallitto M.,
    10. Donahue L.,
    11. Chu G.,
    12. Torraca G.,
    13. Vance A.,
    14. Mire-Sluis T.,
    15. Freund E.,
    16. Davis J.,
    17. Narhi L.

    Tungsten-induced protein aggregation: solution behavior. J. Pharm. Sci. 2009, 98 (12), 4695–4710.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Liu D.,
    2. Nashed-Samuel Y.,
    3. Bondarenko P. V.,
    4. Brems D. N.,
    5. Ren D.

    Interactions between Therapeutic Proteins and Acrylic Acid Leachable. PDA J. Pharm. Sci. Technol. 2012, 66 (1), 12–19.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Shin J. U.,
    2. Park J. L.,
    3. Liu C.,
    4. He J.,
    5. Kim S. C.

    Chemical Structure and Physical Properties of Cyclic Olefin Copolymers. Pure Appl. Chem. 2005, 77 (5), 801–814.

    OpenUrl
14. 14.↵
    1. Nema S.,
    2. Ludwig J. D.

    1. Vilivalam V. V.,
    2. DeGrazio F. L.

    Plastic Packaging for Farenteral Drug Delivery. In Pharmaceutical Dosage Forms: Parenteral Medications, Nema S., Ludwig J. D., Eds.; Informa Healthcare: New York, 2010; Volume 1.
15. 15.↵
    1. Yoshino K.,
    2. Nakamura K.,
    3. Yamashita A.,
    4. Abe Y.,
    5. Iwasaki I.,
    6. Kanazuma Y.,
    7. Funatsu K.,
    8. Yoshimoto T.,
    9. Suzuki S.

    Functional Evaluation and Characterization of a Newly Developed Silicone Oil–Free Prefillable Syringe System. J. Pharm. Sci. 2014, 103 (5), 1520–1528.

    OpenUrlPubMed
16. 16.↵
    1. Kamerzell T. J.,
    2. Li M.,
    3. Arora S.,
    4. Ji J. A.,
    5. Wang Y. J.

    The Relative Rate of Immunoglobulin Gamma 1 Fragmentation. J. Pharm. Sci. 2011, 100 (4), 1341–1349.

    OpenUrl
17. 17.↵
    1. Vlasak J.,
    2. Ionescu R.

    Fragmentation of Monoclonal Antibodies. mAbs 2011, 3 (3), 253-263.

    OpenUrlCrossRefPubMed
18. 18.↵
    Bristol-Myers Squibb. Accessed at http://packageinserts.bms.com/pi/piorencia.pdf. Accessed on January 13, 2012.
19. 19.↵
    1. Majumdar S.,
    2. Ford B. M.,
    3. Mar K. D.,
    4. Sullivan V. J.,
    5. Ulrich R. G.,
    6. D'Souza A. J. M.

    Evaluation of the Effect of Syringe Surfaces on Protein Formulations. J. Pharm. Sci. 2011, 100 (7), 2563–2573.

    OpenUrlPubMed
20. 20.↵
    1. Krayukhina E.,
    2. Tsumoto K.,
    3. Uchiyama S.,
    4. Fukui K.

    Effects of Syringe Material and Silicone Oil Lubrication on the Stability of Pharmaceutical Proteins. J. Pharm. Sci. 2015, 104 (2), 527–535.

    OpenUrlPubMed
21. 21.↵
    1. Weiss W. F. IV.,
    2. Hodgdon T. K.,
    3. Kaler E. W.,
    4. Lenhoff A. M.,
    5. Roberts C. J.

    Nonnative Protein Polymers: Structure, Morphology, and Relation to Nucleation and Growth. Biophys. J. 2007, 93 (12), 4392–4403

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Sluzky V.,
    2. Tamada J. A.,
    3. Klibanov A. M.,
    4. Langer R.

    Kinetics of Insulin Aggregation in Aqueous Solutions upon Agitation in the Presence of Hydrophobic Surfaces. Proc. Natl. Acad. Sci. U. S. A. 1991, 88 (21), 9377–9381.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    1. Luo Q.,
    2. Joubert M. K.,
    3. Stevenson R.,
    4. Ketchem R. R.,
    5. Narhi L. O.,
    6. Wypych J.

    Chemical Modifications in Therapeutic Protein Aggregates Generated under Different Stress Conditions. J. Biol. Chem. 2011, 286 (28), 25134–25144.

    OpenUrlAbstract/FREE Full Text
24. 24.↵
    1. Patel J.,
    2. Kothari R.,
    3. Tunga R.,
    4. Ritter N. M.,
    5. Tunga B. S.

    Stability Considerations for Biopharmaceuticals, Part 1: Overview of Protein and Peptide Degradation Pathways. BioProcess International 2011, 9 (1), 20–31.

    OpenUrl
25. 25.↵
    1. Puri M.,
    2. Morar-Mitrica S.,
    3. Crotts G.,
    4. Nesta D.

    Evaluating Freeze-Thaw Processes in Biopharmaceutical Development. BioProcess International 2015, 13 (1), 34–45.

    OpenUrl
26. 26.↵
    1. Labrenz S. R.,
    2. Calmann M. A.,
    3. Heavner G. A.,
    4. Tolman G.

    The Oxidation of Methionine-54 of Epoetinum Alfa Does Not Affect Molecular Structure or Stability, but Does Decrease Biological Activity. PDA J. Pharm. Sci. Technol. 2008, 62 (3), 211–223.

    OpenUrlAbstract/FREE Full Text
27. 27.↵
    1. Waterman K. C.,
    2. Adami R. C.,
    3. Alsante K. M.,
    4. Hong J.,
    5. Landis M. S.,
    6. Lombardo F.,
    7. Roberts C. J.

    Stabilization of Pharmaceuticals to Oxidative Degradation. Pharm. Dev. Technol. 2002, 7 (1), 1–32.

    OpenUrlPubMed
28. 28.↵
    1. Li S.,
    2. Schöeneich C.,
    3. Borchardt R. T.

    Chemical Instability of Protein Pharmaceuticals: Mechanisms of Oxidation and Strategies for Stabilization. Biotechnol. Bioeng. 1995, 48 (5), 490–500.

    OpenUrlCrossRefPubMedWeb of Science
29. 29.↵
    1. Kerwin B. A.,
    2. Remmele R. I. Jr..

    Protect from Light: Photodegradation and Protein Biologics. J. Pharm. Sci. 2007, 96 (6), 1468–1479.

    OpenUrlCrossRefPubMed
30. 30.↵
    1. Nakamura K.,
    2. Abe Y.,
    3. Kiminami H.,
    4. Yamashita A.,
    5. Iwasaki K.,
    6. Suzuki S.,
    7. Yoshino K.,
    8. Dierick W.,
    9. Constable K.

    A Strategy for the Prevention of Protein Oxidation by Drug Product in Polymer-Based Syringes. PDA J. Pharm. Sci. Technol. 2015, 69 (1), 88–95.

    OpenUrlAbstract/FREE Full Text
31. 31.↵
    1. Nakamura K.,
    2. Kiminami H.,
    3. Yamashita A.,
    4. Abe Y.,
    5. Yoshino K.,
    6. Suzuki S.

    Assessment of the Effects of Sterilization Methods on Protein Drug Stability by Elucidating Decomposition Mechanism and Material Analysis. Int. J. Pharm. 2015, 484 (1-2), 51–56.

    OpenUrlPubMed
32. 32.↵
    1. Basu P.,
    2. Krishnan S.,
    3. Thirumangalathu R.,
    4. Randolph T. W.,
    5. Carpenter J. F.

    IgG1 Aggregation and Particle Formation Induced by Silicone-Water Interfaces on Siliconized Borosilicate Glass Beads: A Model for Siliconized Primary Containers. J. Pharm. Sci. 2013, 102 (3), 852–865.

    OpenUrl